- Location
orally disintegrating tablets
"-
The USFDA Has Cleared Actavis's ANDA for Lamotrigine Orally Disintegrating Tablets
Jul 17, 2013The USFDA has cleared Actavis' abbreviated new drug application (ANDA) for Lamotrigine orally disintegrating tablets, 25mg, 50mg, 100mg and 200mg. A generic version of GlaxoSmithKline's Lamictal ODT, the antiepileptic drug is indicated ...
-
Impax Laboratories Has Introduced Authorized Generic of Zomig Tablets
May 21, 2013Impax Laboratories has introduced authorized generic of Zomig (zolmitriptan) tablets and orally disintegrating tablets, 2.5mg and 5mg, in the US. Global Pharmaceuticals, the generics division of Impax, commenced product shipment, as part ...
Tags: Impax Introduces, Generic of Zomig
-
Dr. Reddy's Laboratories Has Received The FDA Approval and Introduced Desloratadine ODT
Jan 29, 2013Dr. Reddy's Laboratories has received the FDA approval and introduced Desloratadine orally disintegrating tablets (ODT) in 2.5mg and 5mg strengths in the US. Desloratadine ODT is a generic equivalent to Clarinex Reditabs (desloratadine), ...
Tags: Desloratadine ODT, ODT, dose
-
FDA Has Approved Mylan Pharmaceuticals' Abbreviated New Drug Applications
Jan 4, 2013The US Food and Drug Administration (FDA) has approved Mylan Pharmaceuticals' abbreviated new drug applications (ANDA) for the generic equivalents to Merck's Maxalt MLT tablets and Maxalt tablets. Rizatriptan Benzoate orally ...
Tags: US, FDA, Mylan Pharmaceuticals, ANDA, Maxalt MLT tablets, Maxalt tablets
-
Mylan Has Signed a Settlement and License Agreements with Shionogi and CIMA Labs
Dec 7, 2012Mylan has signed a settlement and license agreements with Shionogi and CIMA Labs regarding Prednisolone sodium phosphate orally disintegrating tablets (ODT), known generically as Orapred ODT. Mylan said that following the settlement ...
-
Akrimax Pharmaceuticals Introduced Suprenza ODT for The Management of Exogenous Obesity
Nov 30, 2012Akrimax Pharmaceuticals has introduced Suprenza (phentermine HCl) orally disintegrating tablets (ODT) for the management of exogenous obesity. The company has launched Suprenza ODT in 15mg and 30mg dosage strengths. Suprenza is ...
Tags: pharceumatical product, obesity drugs, clinical research
